Genetics Generation Advancement Corp. (4160.TWO)

TWD 54.2

(3.83%)

EBITDA Summary of Genetics Generation Advancement Corp.

  • Genetics Generation Advancement Corp.'s latest annual EBITDA in 2023 was 50.6 Million TWD , up 11.64% from previous year.
  • Genetics Generation Advancement Corp.'s latest quarterly EBITDA in 2024 Q2 was 26.72 Million TWD , up 21.17% from previous quarter.
  • Genetics Generation Advancement Corp. reported an annual EBITDA of 44.72 Million TWD in 2022, up 118.37% from previous year.
  • Genetics Generation Advancement Corp. reported an annual EBITDA of 20.47 Million TWD in 2021, up 291.77% from previous year.
  • Genetics Generation Advancement Corp. reported a quarterly EBITDA of 22.06 Million TWD for 2024 Q1, up 72.01% from previous quarter.
  • Genetics Generation Advancement Corp. reported a quarterly EBITDA of 12.82 Million TWD for 2023 Q4, up 26.12% from previous quarter.

Annual EBITDA Chart of Genetics Generation Advancement Corp. (2023 - 2019)

Historical Annual EBITDA of Genetics Generation Advancement Corp. (2023 - 2019)

Year EBITDA EBITDA Growth
2023 50.6 Million TWD 11.64%
2022 44.72 Million TWD 118.37%
2021 20.47 Million TWD 291.77%
2020 -10.91 Million TWD -167.2%
2019 15.89 Million TWD 0.0%

Peer EBITDA Comparison of Genetics Generation Advancement Corp.

Name EBITDA EBITDA Difference
BIONET Corp. 147.09 Million TWD 65.598%
DIVA Laboratories, Ltd. 100.31 Million TWD 49.556%
Welgene Biotech Co.,Ltd. 26.83 Million TWD -88.564%
Puriblood Medical Co., Ltd. -44.01 Million TWD 214.967%
TFBS Bioscience Inc. 64.15 Million TWD 21.119%